These findings agree with those of FLAURA, FLAURA2 and recent meta-analyses, which have established osimertinib as the most effective treatment for advanced EGFR-mutated NSCLC [14,16,17,28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.